GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » Price-to-Owner-Earnings

GCTK (GlucoTrack) Price-to-Owner-Earnings : (As of Apr. 13, 2025)


View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack Price-to-Owner-Earnings?

As of today (2025-04-13), GlucoTrack's share price is $0.1625. GlucoTrack does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for GlucoTrack's Price-to-Owner-Earnings or its related term are showing as below:


GCTK's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 28.34
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-13), GlucoTrack's share price is $0.1625. GlucoTrack's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-59.18. Therefore, GlucoTrack's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-13), GlucoTrack's share price is $0.1625. GlucoTrack's EPS without NRI for the trailing twelve months (TTM) ended in was $-59.18. Therefore, GlucoTrack's PE Ratio without NRI for today is At Loss.

During the past 13 years, GlucoTrack's highest PE Ratio without NRI was 46.87. The lowest was 0.00. And the median was 30.94.


GlucoTrack Price-to-Owner-Earnings Historical Data

The historical data trend for GlucoTrack's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack Price-to-Owner-Earnings Chart

GlucoTrack Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlucoTrack Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlucoTrack's Price-to-Owner-Earnings

For the Medical Instruments & Supplies subindustry, GlucoTrack's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlucoTrack's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where GlucoTrack's Price-to-Owner-Earnings falls into.


;
;

GlucoTrack Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

GlucoTrack's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1625/-28.14
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlucoTrack  (NAS:GCTK) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


GlucoTrack Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of GlucoTrack's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


GlucoTrack Business Description

Traded in Other Exchanges
N/A
Address
301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
Executives
Drew Sycoff director C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
James S Cardwell officer: Chief Financial Officer CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter director 301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig director 301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps director C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
David Podwalski officer: Chief Commercial Officer 19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham director, officer: Chief Executive Officer 19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun officer: Chief Financial Officer 39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff director 1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Leslie Seff director PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Angela Strand Boydston director C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Eran Hertz officer: Chief Financial Officer C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich director C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100